ProfileGDS5678 / 1448774_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 91% 90% 89% 90% 92% 90% 91% 91% 90% 91% 90% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.3207591
GSM967853U87-EV human glioblastoma xenograft - Control 27.4697191
GSM967854U87-EV human glioblastoma xenograft - Control 37.2773490
GSM967855U87-EV human glioblastoma xenograft - Control 47.1785789
GSM967856U87-EV human glioblastoma xenograft - Control 57.3609390
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4201592
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0438290
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.3262891
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.3480591
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3332990
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.461491
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3274890
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3376191
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3725791